Integrilin

Eptifibatide, the active ingredient in Integrilin, is a glycoprotein IIb/IIIa inhibitor presented as an injection for intravenous use. It is employed in the management of acute coronary syndrome and during percutaneous coronary intervention to prevent platelet aggregation in at‑risk patients.

GNH USA supplies Integrilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Integrilin (eptifibatide) is used within the antiplatelet therapy pathway for cardiovascular emergencies.

Acute coronary syndrome: reduces the incidence of ischemic complications during acute management. Unstable angina/NSTEMI: provides rapid platelet inhibition to improve coronary blood flow. Percutaneous coronary intervention: prevents thrombotic occlusion of the treated vessel during and after the procedure.

Eptifibatide may be associated with a range of adverse reactions.

Common Side Effects: - Bleeding at the injection site - Minor bruising or hematoma - Mild thrombocytopenia - Nausea or vomiting - Transient hypotension

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Thrombocytopenia with platelet count <50,000/µL - Acute coronary thrombosis despite therapy - Anaphylactic or hypersensitivity reactions - Hemolytic anemia

When using Integrilin, clinicians should consider several safety measures.

Renal impairment: adjust infusion rate and monitor renal function. Recent surgery or trauma: evaluate bleeding risk before initiation. Concurrent anticoagulants: assess cumulative anticoagulation effect. History of bleeding disorders: use with caution and monitor closely. Pregnancy and lactation: safety not established; weigh benefits against risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Eptifibatide can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concurrent use of other glycoprotein IIb/IIIa inhibitors - High‑dose unfractionated heparin - Direct thrombin inhibitors (e.g., bivalirudin)

Moderate Interactions (Monitor Closely): - Low‑molecular‑weight heparins - Oral anticoagulants (warfarin, DOACs) - Antiplatelet agents such as aspirin or clopidogrel - Non‑steroidal anti‑inflammatory drugs (NSAIDs) - Fibrinolytic therapy